University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
E-Cigarettes are Expanding Tobacco Product Use Among Youth

E-Cigarettes are Expanding Tobacco Product Use Among Youth

January 23, 2017

E-cigarettes – thought by some to be responsible for a decline in youth cigarette smoking – are actually attracting a new population of adolescents who might not otherwise have smoked tobacco products, according to a new UC San Francisco study.

Successful Immunotherapy Requires System-Wide Immune Response

Successful Immunotherapy Requires System-Wide Immune Response

January 20, 2017

New research led by researchers from UC San Francisco and Stanford University has found that successful cancer immunotherapy appears to depend on whether the treatment can trigger a system-wide immune response, rather than just a local response within the tumor itself.

Largest-Ever Gift to UCSF Honors Philanthropist Helen Diller

Largest-Ever Gift to UCSF Honors Philanthropist Helen Diller

January 12, 2017

To honor and build on a lifetime of giving and charitable service by the late Helen Diller, the Helen Diller Foundation has granted $500 million to UC San Francisco, a university to which Helen was both generous and devoted. The gift will be the largest ...
HDFCCC Joins National Effort Endorsing Updated HPV Vaccine Recommendations

HDFCCC Joins National Effort Endorsing Updated HPV Vaccine Recommendations

January 10, 2017

Recognizing a critical need to improve national vaccination rates for the human papillomavirus (HPV), the UCSF Helen Diller Family Comprehensive Cancer Center has again united with each of the 69 National Cancer Institute (NCI)-designated cancer centers in issuing a joint statement in support of recently revised recommendations from the Centers for Disease Control and Prevention (CDC).

UCSF, Pfizer Renew Research Collaboration, Citing Progress in Drug Discovery Research

UCSF, Pfizer Renew Research Collaboration, Citing Progress in Drug Discovery Research

January 9, 2017

UC San Francisco and Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) have renewed an agreement to identify and develop biologic compounds against both known and novel targets, including the immune system, in diseases such as cancer, cardiovascular and metabolic diseases. The collaboration allows UCSF and ...
The Role of Common Risk Factors in ER-positive, ER-negative Breast Cancer

The Role of Common Risk Factors in ER-positive, ER-negative Breast Cancer

January 9, 2017

Karla Kerlikowske, MD, and team recently published a paper in the Journal of the National Cancer Institute that examined the role of common risk factors in the development of ER-positive and ER-negative breast cancers. The study sheds new light on how a woman's age, weight, ...